Coherus Oncology, Inc. (CHRS) Q3 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Coherus Oncology, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:05.437 Results may vary significantly, and we undertake no duty to update or revise any forward-looking 00:00:05.437 -- 00:00:06.878 statements. 00:00:06.878 -- 00:00:11.644 Please see the press release that we issued today and our quarterly report on Form 10-Q 00:00:11.644 -- 00:00:14.887 for more information on risks and uncertainties. 00:00:14.887 -- 00:00:17.170 And now I'd like to turn the call over to Denny. 00:00:17.170 -- 00:00:22.796 Thank you, Carrie, and good afternoon, everyone, and welcome to our Q3 2025 earnings 00:00:22.796 -- 00:00:24.398 call. 00:00:24.398 -- 00:00:29.725 As we get started, let me first welcome Arvind Su to Coherence Oncology, our newly appointed 00:00:29.725 -- 00:00:32.810 Chief Strategy and Corporate Affairs Officer. 00:00:32.810 -- 00:00:38.838 Arvind is responsible for investor relations, corporate development, and government affairs. 00:00:38.838 -- 00:00:40.661 Welcome, Arvind. 00:00:40.661 -- 00:00:43.765 Thank you. Things are going very well, and today I'm very excited to tell you about the 00:00:43.765 -- 00:00:48.652 progress we have made on our strategic plan in the last quarter, as well as generally 00:00:48.652 -- 00:00:54.672 recap our progress for you over the past year as we approach the end of 2025. 00:00:54.672 -- 00:00:59.798 As you know, we take great pride in our ability to execute, and execution has been strong 00:00:59.798 -- 00:01:04.604 across the board. For example, you may recall last year me telling you that our objectives 00:01:04.604 -- 00:01:10.691 included driving the top line, reducing expenses, and strengthening the balance sheet. 00:01:10.691 -- 00:01:14.837 I'm happy to report we've made great progress across all three. 00:01:14.837 -- 00:01:19.002 We are particularly ...